Anti Vegf Eylea Hd denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Eylea HD (aflibercept 8 mg) as Duplicate Therapy

Eylea HD is the higher-concentration, longer-interval formulation of aflibercept. A duplicate-therapy denial from Humana typically means the plan's system detected an active authorization or recent claim for another anti-VEGF agent — which may include the original Eylea 2 mg formulation — and flagged the two as therapeutically equivalent. This is a particularly common error during transitions between the two aflibercept products, because switching from Eylea 2 mg to Eylea HD is a deliberate clinical choice to extend injection intervals, not a duplication of care.

## Why This Denial Is Appealable

The duplicate-therapy rationale fails when the prescriber has documented a clinical distinction between the two agents. Eylea HD's FDA-approved labeling covers extended dosing intervals not available with the 2 mg formulation; a transition to Eylea HD for interval extension is a clinically meaningful change in regimen, not a duplicative one. If the prior authorization for Eylea 2 mg is stale or was never reversed, the administrative record can be corrected. The appeal must establish both the clinical rationale for the transition and the absence of true concurrent therapy.

## Your Federal Appeal Rights

• Internal appeal: File under your plan's internal grievance process (ACA-compliant Humana commercial plans) or ERISA §503 (employer-sponsored plans) within the deadline on your denial letter.
• External review (ACA §2719): If Humana upholds the denial internally, escalate to an Independent Review Organization within approximately four months of the initial denial. The IRO reviews the clinical record independently and is not bound by Humana's determination.
• Expedited review: If ongoing injections are at risk and a lapse would harm your vision, request the 72-hour expedited track simultaneously with the internal appeal.

## Documentation to Gather

1. Active authorization audit — request a report of every active or pending anti-VEGF authorization in your Humana file; identify any stale Eylea 2 mg authorization that should be closed. 2. Transition rationale — chart notes documenting the prescriber's decision to switch from Eylea 2 mg to Eylea HD, including the clinical objective (e.g., interval extension, patient burden reduction) and the disease-activity status at the time of transition. 3. Injection timeline — a complete log of prior anti-VEGF injections showing no true concurrent use of both formulations. 4. FDA label for Eylea HD — the current prescribing information confirming the approved indications and the extended-interval dosing option that differentiates it from Eylea 2 mg. 5. Prescriber letter — a signed statement explaining why Eylea HD is not duplicative and what specific clinical goal the transition serves, addressed to Humana's anti-VEGF coverage criteria.

## Criteria-Mapping Structure

For this denial type, your criteria map should first address the duplication question directly: in the left column, state Humana's duplicate-therapy definition from its published anti-VEGF policy; in the right column, document the clinical distinction between the two agents and confirm no concurrent use. Then complete a standard medical-necessity map for Eylea HD, covering each eligibility criterion in Humana's policy with the supporting chart evidence.